Abstract
Background
In drug development, the safety of a test drug for human use is first assessed in animal toxicology studies; therefore, the no-observed-adverse-effect-level (NOAEL) and toxicokinetic data are very important for the evaluation of clinical safety. The ratio of drug exposure in animals at the NOAEL to that of humans at the expected therapeutic dose is one of the primary measures for determining the risk-benefit profile of a pharmaceutical. The objective of this study was to evaluate the safety profiles of drugs for blood cancer approved in Japan by examining safety indices (SIs).
Methods
SIs were calculated as animal-to-human ratios in doses and exposure using NOAEL, severely toxic dose 10% of the animals, highest nonseverely toxic dose, maximum approved dose, and exposure levels (Cmax and area under the curve [AUC]) at the NOAEL and maximum approved dose. If the SI of a certain drug is <1.0, either the maximum therapeutic dose exceeds the NOAEL, or the exposure level at the maximum therapeutic dose exceeds the exposure level at the NOAEL.
Results
A total of 8 of 17 SIs by dose were <1.0; 6 of 8 SIs by Cmax were <1.0, and 6 of 9 SIs by AUC were <1.0.
Conclusions
In cases where the SI is <1.0, no drug safety margin can be assured based on animal data. When extrapolating data from animal studies to safety assessment in clinical studies, safety profile would be one of aspects to be carefully considered in drug development, including postmarketing surveillance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
ICH. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf. Published June 11, 2009. Accessed July 11, 2015.
ICH. General considerations for clinical trials E8. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E8/Step4/E8_Guideline.pdf. Published July 1997. Accessed August 22, 2015.
ICH. Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies S3A. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S3A/Step4/S3A_Guideline.pdf. Published October, 1994. Accessed August 22, 2015.
FDA. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf. Published July 2005. Accessed July 25, 2015.
MHLW. Guidance for establishing safety in first-in-human studies during drug development. Published April 2, 2012.
ICH. Nonclinical evaluations for anticancer pharmaceuticals S9. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S9/Step4/S9_Step4_Guideline.pdf. Published October 2009. Accessed October 1, 2015.
ICH. Pharmacovigilance planning E2E. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2E/Step4/E2E_Guideline.pdf. Published November 2004. Accessed October 1, 2015.
MHLW. Notification No. 0411-(1) of the safety division of PFSB and no. 0411-(2) of the evaluation and licensing division of PFSB. Published April 11, 2012.
NHLW. The Ministerial Ordinance on Good Vigilance Practice for drugs, quasi-drugs, cosmetics, and medical devices. MHLW Ministerial Ordinance No. 135. Published September 22, 2004.
ICH. Organization of the common technical documents for the registration of pharmaceuticals for human use M4. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/CTD/M4_R3_Organisation/M4_R3__organisation.pdf. Published January, 2004. Accessed August 22, 2015.
NHLW. The standards for the conduct of clinical studies. MHLW Ministerial Ordinance No. 28. Published March 27, 1997.
NHLW. The ordinance on standards for conduct of nonclinical studies on the safety of drugs. MHLW Ministerial Ordinance No.21. Published March 26, 1997.
ICH. Ethnic factors in the acceptability of foreign clinical data E5(R1). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1__Guideline.pdf. Published February 1998. Accessed October 5, 2015.
Kato R, Yasumori T. Comparative study on pharmacokinetic and toxicokinetic parameters between the human clinical dose and animal nontoxic dose in new drug development. Jpn J Clin Pharmacol Ther. 1996; 27:759–769.
Kayama M, Narukawa M. Consideration of factors affecting the safety index in early clinical drug development. Therapeutic Innovation & Regulatory Science. 2014; 48:436–443.
ICH. Preclinical safety evaluation of biotechnology-derived pharmaceuticals S6(R1). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf. Published June 2011. Accessed August 22, 2015.
FDA. Guidance for industry reproductive and developmental toxicities—integrating study results to assess concerns. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079240.pdf. Published September 2011. Accessed August 22, 2015.
Author information
Authors and Affiliations
Corresponding author
Additional information
Author Note
This article was presented at the Student Poster Session of DIA 2015 51st Annual Meeting, June 15, 2015, in Washington, DC.
Rights and permissions
About this article
Cite this article
Kubota, S., Saito, K., Ono, S. et al. Evaluation of Safety Profiles of Blood Cancer Drugs Approved in Japan. Ther Innov Regul Sci 50, 228–235 (2016). https://doi.org/10.1177/2168479015619658
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479015619658